My Site Title
My Site Tagline
My Site Tagline
UNIS: $10 million of additional Orbimed funding
Bristol-Myers JV licenses immuno-oncology assets from Yale
Sentiment Update
MiMedx: A Mispriced Growth Stock Poised For Outsized Gains
QUIK: Misses 3Q'15 revenue estimates
MDXG Analyst Day
MDXG: Qui Tam Complaint Against MiMedx is Fully Dismissed
CGEN: ADC Program Update
EZCH being acquired by MLNX
CGEN: Sept Corp Presentation
EZCH Proxy Statement
EZCH: Raging Capital a "NO" vote
CGEN: FPRX/BMY Provides Deal Valuation Comp
EZCH saga continues... Raging Capital nominates two for BOD
Uni-Pixel: A Speculative Dark Horse As We Round Out 2015
MDXG: 3Q'15 results
UNIS: 1Q'16 preliminary results
CGEN: 3Q'15 Quarterly Review
UNIS: Buy Reiterated at Griffin Securities
MDXG: White Paper
Sentiment Update
MiMedx (MDXG) vs Osiris (OSIR)
Unilife (UNIS): 1Q'16 results
UNIS: Griffin Securities recap of Annual General Meeting
MiMedix (MDXG): Revenue Model
CGEN: November Corporate Presentation
Sentiment Update for December 1
MedImmune Presentation on Wearable Injectors
Sentiment Update for January 4
Sentiment Update: January 7
A Market Low?
Developing combination immunotherapies against cancer that make sense
CGEN: 11/7/18 Oppenheimer report
Hashgraph Exchange: A White Paper
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8þ T-cell Function
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
The Role of PVRIG in Liver Cancer
Citibank's View of Roche's TIGIT